| Delmonte, Angelo |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
| Recruiting | 3 | 162 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Placebo | Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A. | Mesotheliomas Pleural | 12/23 | 12/23 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) |
|
|
| Recruiting | 2 | 49 | Europe | Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion | Gruppo Oncologico Italiano di Ricerca Clinica | Pulmonary Large-cell Neuroendocrine Carcinoma | 12/26 | 12/26 | | |
| Completed | 2 | 90 | Europe, US | avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063 | Verastem, Inc. | Non Small Cell Lung Cancer, KRAS Activating Mutation | 08/23 | 12/23 | | |
|
COMBI-TED, NCT04884282 / 2020-005170-10: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) |
|
|
| Recruiting | 2 | 105 | Europe | Tedopi, Nivolumab, Docetaxel | Fondazione Ricerca Traslazionale, Bristol Myer Squibb International Corporation, OSE Immunotherapeutics | Metastatic Non Small Cell Lung Cancer | 10/23 | 05/25 | | |
| Active, not recruiting | 2 | 217 | Europe, Japan, US, RoW | tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex | Seagen Inc., Seagen, Inc. | Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms | 11/23 | 05/25 | | |
| Recruiting | 2 | 170 | Europe | Osimertinib, Tagrisso, Dacomitinib, Vizimpro | Fondazione Ricerca Traslazionale, Pfizer srl | NSCLC | 12/23 | 12/23 | | |
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
|
|
| Not yet recruiting | 2 | 142 | Europe | Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide | Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 08/28 | 06/29 | | |
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC |
|
|
| Recruiting | 2 | 44 | Europe | Niraparib | ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited | SCLC,Extensive Stage, SLFN11-positive | 05/25 | 10/25 | | |
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 2 | 176 | Europe, Canada, US, RoW | Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608 | GlaxoSmithKline, iTeos Belgium SA | Neoplasms | 05/24 | 05/24 | | |
| Terminated | 2 | 6 | Europe, RoW | Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT) | ETOP IBCSG Partners Foundation, AstraZeneca | NSCLC Stage IV, EGFR Gene Mutation | 10/23 | 02/24 | | |
| Recruiting | 2 | 60 | Europe | Pembrolizumab/Olaparib | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC | SCLC,Extensive Stage | 10/26 | 10/26 | | |
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 44 | Europe | Brigatinib, Durvalumab | ETOP IBCSG Partners Foundation, Takeda | NSCLC, Stage III, ALK-rearrangement | 09/24 | 09/24 | | |
| Active, not recruiting | 1/2 | 284 | Europe, Japan, US, RoW | CLN-081, TAS6417; zipalertinib | Cullinan Therapeutics Inc. | Non Small Cell Lung Cancer, EGFR Exon 20 Mutation | 12/24 | 12/24 | | |
|
| Tiseo, Marcello |
| Active, not recruiting | 3 | 125 | Europe | Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care | Gruppo Oncologico Italiano di Ricerca Clinica, Mipharm S.p.A., Bioikos Ambiente Srl, Istituto Toscano Tumori, Temas srl, Bristol Myers Squibb Srl Italia | Squamous Non-small Cell Lung Cancer | 01/23 | 01/23 | | |
| Recruiting | 3 | 162 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Placebo | Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A. | Mesotheliomas Pleural | 12/23 | 12/23 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Completed | 2 | 90 | Europe, US | avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063 | Verastem, Inc. | Non Small Cell Lung Cancer, KRAS Activating Mutation | 08/23 | 12/23 | | |
|
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial) |
|
|
| Completed | 2 | 43 | Europe | Atezolizumab | Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA | Non-Small Cell Lung Cancer | 02/24 | 02/24 | | |
CHIMERA, NCT06155279: Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma ( Study) |
|
|
| Recruiting | 2 | 40 | Europe | Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab, Keytruda | Istituto Oncologico Veneto IRCCS, MSD Italia S.r.l. | Pleural Mesothelioma | 03/26 | 03/27 | | |
AUSTRAL, NCT06680050: Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen |
|
|
| Not yet recruiting | 2 | 21 | Europe | Durvalumab (MEDI4736), Ceralasertib, radiotherapy | Mario Negri Institute for Pharmacological Research | Non Small Cell Lung Cancer NSCLC | 01/27 | 01/28 | | |
| Active, not recruiting | 1/2 | 429 | Europe, US, RoW | Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Genmab, BioNTech SE | Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer | 02/26 | 02/26 | | |
| Recruiting | N/A | 220 | Europe | Translation analysis | Istituto Oncologico Veneto IRCCS | Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung | 12/26 | 12/26 | | |
NCT04416672: Validation of the Italian Version of the PRO-CTCAE |
|
|
| Recruiting | N/A | 3675 | Europe | PRO-CTCAE items | National Cancer Institute, Naples | Malignant Neoplasms | 07/24 | 07/24 | | |
